A genome-wide CRISPR/Cas9 screening found that the loss of Kelch-like ECH-associated protein 1 (KEAP1) (464) and SGOL1 (465) promote drug resistance in cancer cells, and the CRISPR-induced deletion of SLFN11 (466), BAK (467), and any CST complex members (468) can initiate drug resistance in cancer cells. This evidence concerns the gene BAK1 and cancer.